Point of care INR monitoring in cyanotic congenital heart disease-related compensatory erythrocytosis.

ABSTRACT:

Introduction

People with cyanotic congenital heart disease (CHD) frequently require anticoagulation with warfarin. Point of care (POC) devices offer significant benefits such as patient-managed warfarin and rapid testing, however, there is limited experience with the use of POC in adult patients with CHD and high haematocrit.

Methods

This exploratory prospective cohort study recruited people between September 2021 and December 2023. Inclusion criteria were cyanotic CHD and oxygen saturations <93% and a Hct ≥0.51. Exclusion criteria were pregnancy, antiplatelet agents, recent thromboembolic event or major medical illness. A Coaguchek XS (Roche Diagnostics) was used.

Results

Five individuals were recruited to the warfarin group (Hct 0.54, 0.52-0.58, IQR 0.04) and five t

SUBMITTER: Rueter P 

PROVIDER: S-EPMC12907891 | biostudies-literature | 2026 Mar

REPOSITORIES: biostudies-literature